SEARCH

SEARCH BY CITATION

References

  • 1
    Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy and insulin resistance due to HIV protease inhibitors. AIDS 1998; 12: F51F58.
  • 2
    Wanke CA. Epidemiological and clinical aspects of the metabolic complications of HIV infection: the fat redistribution syndrome. AIDS 1999; 13: 12871293.
  • 3
    Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 20932099.
  • 4
    Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999; 13: 24932505.DOI: 10.1097/00002030-199912240-00002
  • 5
    Kotler DP. (Please give title of presentation.) Antiviral Ther 1999; 4 (Suppl. 2): 17.
  • 6
    Jaeger H, Wolf E, Hammel G et al. HAART is not hard enough: virological failure after 12 months of treatment in antiretroviral therapy-naive HIV+ patients. 12th World AIDS Conference. Geneva, Switzerland, July 2000 [Abstract 32319].
  • 7
    World Health Organization Working Group. Use and interpretation of anthropometric indicators of nutritional status. Bull WHO 1986; 643: 929941.
  • 8
    The SAS System. Cary, NC, SAS Institute Inc 1999.
  • 9
    Viard JP, Rakotoambinina B. Lipodystrophic syndromes in a cohort of HIV-1-infected patients receiving HA antiretroviral therapy with a protease inhibitor. Antiviral Ther 1999; 4 (Suppl. 2): 47[Abstract].
  • 10
    Mallal S, John M, Moore C, James I, Mckinnon E. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14: 13091316.
  • 11
    Bernasconi E, Carota A, Magenta L et al. Metabolic changes in HIV-infected patients treated with protease inhibitors. 12th World AIDS Conference. Geneva, Switzerland, June–July 1998 [Abstract 12375].
  • 12
    Bonnet E, Cuzin L, Sailler M et al. Associated lipodystrophy metabolic disorders due to protease inhibitor containing regimen. 12th World AIDS Conference. Geneva, Switzerland, June–July 1998 [Abstract 12299].
  • 13
    Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998; 12: F37F39.
  • 14
    El-Sadr WM, Collins G, Raghavan S et al. Prevalence of metabolic complications in a large diverse cohort of HIV-infected persons. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, January–February 2000 [Abstract 13].
  • 15
    Molina JM, Angelini E, Cotte L et al. Prevalence of lipodystrophy in the long-term follow-up of a clinical trial comparing various combinations of nucleoside reverse transcriptase inhibitors, ALBI trial (ANRS 070). 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, January–February 2000 [Abstract 19].
  • 16
    Saint-Marc T, Partisani M, Poizon-Martin I et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000; 14: 3749.
  • 17
    Saint-Marc T, Partisani M, Poizot-Martin I et al. A syndrome of peripheral fat wasting (lipodystropy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13: 16591667.
  • 18
    Polo R, Verdejo J, Gonzales-Munoz M et al. Lipodystrophy related to NRT inhibitors in HAART. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, October 1999 [Abstract 1302].
  • 19
    Brinkman K, Smeitink JA, Romijn HA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-related lipodystrophy. Lancet 1999; 354: 11121115.
  • 20
    Carr A, Miller J, Law M, Cooper DA. A syndrome of lipodystrophy (LD), lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue reverse transcriptase inhibitor therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000; 14: F25F32.DOI: 10.1097/00002030-200002180-00001
  • 21
    Tashima K, Stryker R, Skiest D et al. Lack of clinical lipodystrophy in patients receiving efavirenz+ NRTIs in study 006. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, October 1999 [Abstract 1304].
  • 22
    Mildvan D, Machado SG, Wilets I, Grossberg SE. Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex. Lancet 1992; 339: 453456.
  • 23
    Sellmeyer DE, Grunfeld C. Endocrine and metabolic disturbance in human immunodeficieny virus infection and the acquired immune deficiency syndrome. Endocr Rev 1996; 17: 518532.
  • 24
    Emilie D, Galanaud P. Cytokines and chemokines in HIV-infections: implications for therapy. Int Rev Immunol 1998; 16: 705726.
  • 25
    Thiébaut R, Daucourt V, Malvy D et al. Lipodystrophy, glucose and lipid metabolism dysfunctions. Aquitaine Cohort, 1999. Antiviral Ther 1999; 4 (Suppl. 2): 41[Abstract].
  • 26
    Behrens G, Dejam A, Schmidt H et al. Impaired glucose tolerance, beta-cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13: F63F70.DOI: 10.1097/00002030-199907090-00001
  • 27
    Purnell JQ, Zambon A, Knopp RH et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000; 14: 5157.DOI: 10.1097/00002030-200001070-00006
  • 28
    Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet, 1998; 351: 18811883.
  • 29
    Kotler DP, Rosenbaum KB, Wang J, Pierson RN Jr. Alterations in body fat distribution in HIV-infected men and women. 12th World AIDS Conference. Geneva, Switzerland, June–July 1998 [Abstract 32173].